Publications & Scientific Contributions
A Chronology of First-in-FieldDiscoveries — and What Followed
Landmark Authored Publications
Geno Marcovici, PhD — corresponding author across the program
Each entry below pairs the published findings with two short commentaries — Significance, identifying the first-in-field contribution, and What Followed, tracing how the broader category subsequently moved in the same direction.
The Library
Five covers. Three decades. One arc.
Hover any cover for the key finding; click to open the source of record.
“Botanical 5α-reductase inhibition in androgenetic alopecia”
2002 — First randomized, double-blind, placebo-controlled clinical evidence that a defined botanical 5-AR inhibitor improves AGA.
“Whole-genome suppression of inflammatory signaling in keratinocytes”
2011 — Transcriptomic proof that AGA-directed botanicals also down-regulate the inflammatory follicular micro-environment.
“Botanical composition outperforms finasteride on androgen markers”
2016 — Head-to-head bench evidence that a multi-component botanical outperforms finasteride on androgen-axis biomarkers.
“β-cyclodextrin nano-inclusion delivery in AGA (TrichoCyte® platform)”
2020 — First clinical use of a cyclodextrin nano-inclusion complex to follicularly target a multi-active botanical regimen.
“Cryo-CO₂ amplification of nano-botanical therapy in advanced AGA”
2025 — Cryo-carboxy amplification compresses prior 9-month phenotypic reversal into 90 days, including in refractory phenotypes.
- 2002
A Randomized, Double-Blind, Placebo-Controlled Trial to Determine the Effectiveness of Botanically Derived Inhibitors of 5-Alpha-Reductase in the Treatment of Androgenetic Alopecia
Prager N, Bickett K, French N, Marcovici G. Journal of Alternative and Complementary Medicine 8(2):143–152
The first published randomized, placebo-controlled clinical trial to demonstrate that naturally derived 5-alpha-reductase inhibitors are effective against androgenetic alopecia. In collaboration with the Clinical Research & Development Network.
Significance — First-in-FieldFirst-in-field. Prior to this paper, botanical 5α-reductase inhibition for AGA was a fringe hypothesis with no Level-1 clinical evidence behind it. This study established the rational, mechanism-based use of a defined botanical 5-AR inhibitor stack as a legitimate therapeutic strategy — opening an entire category that did not previously exist.
What FollowedIn the years that followed, a wave of consumer hair-loss brands re-formulated around saw palmetto and adjacent 5-AR-inhibiting botanicals, frequently citing this trial as justification. The mechanism-of-action narrative our team introduced is now the de facto template used across the natural hair-loss segment.
- 2011
Inhibition of Inflammatory Gene Expression in Keratinocytes Using a Composition Containing Carnitine, Thioctic Acid and Saw Palmetto Extract
Chittur S, Parr B, Marcovici G. Evidence-Based Complementary and Alternative Medicine, 2011: 985345
Genome-wide expression profiling in human HaCaT keratinocytes demonstrating suppression of LPS-activated chemokine and cytokine signaling — including CCL17, CXCL6, and LTB4. Conducted in collaboration with the SUNY Center for Functional Genomics.
Significance — First-in-FieldFirst-in-field demonstration that a defined botanical composition for AGA acts not only on the androgen axis but also down-regulates the inflammatory micro-environment of the follicle at the transcriptomic level. This reframed AGA as a partly inflammatory disease and gave the field its first whole-genome evidence base for multi-pathway, anti-inflammatory follicular therapy.
What FollowedThe 'scalp inflammation' positioning subsequently adopted by major OTC and clinical hair brands traces directly to the gene-expression dataset published here. Competing formulations rapidly added carnitine, alpha-lipoic (thioctic) acid and analogous anti-inflammatory adjuncts to legacy saw-palmetto products — recapitulating the multi-target architecture our group had already disclosed.
- 2016
Blockade of Androgen Markers Using a Novel Betasitosterol, Thioctic Acid and Carnitine-containing Compound in Prostate and Hair Follicle Cell-based Assays
Marcovici G, et al. Phytotherapy Research (Wiley)
Parallel in vitro investigation in hair follicle dermal papilla cells and LNCaP prostate cells, demonstrating mRNA-level down-regulation of disease-associated androgen markers — corroborated at the protein level by western blot and outperforming finasteride in this assay system.
Significance — First-in-FieldFirst peer-reviewed demonstration that a defined, multi-component botanical composition could outperform finasteride on relevant androgen-axis biomarkers in matched dermal-papilla and LNCaP assays — uniting follicular and prostatic biology under a single, naturally derived mechanism-of-action.
What FollowedFollowing publication, competitors broadened their claims from generic '5-AR inhibition' to androgen-receptor and androgen-marker modulation language, and several began benchmarking their actives against finasteride in cell-based assays — directly echoing the comparative framework our group introduced.
- 2020
An Uncontrolled Case Series Using a Botanically Derived β-Cyclodextrin Inclusion Complex in Two Androgenetic Alopecia-Affected Male Subjects
Marcovici G, Bauman A. Cosmetics 7(3):65
Clinical case series of a nanotechnology-enabled β-cyclodextrin inclusion complex (the TrichoCyte® platform), with photographic documentation of hair density improvements at 0, 90, 180, and 270 days. Co-authored with Alan J. Bauman, M.D. of Bauman Medical.
Significance — First-in-FieldFirst reported use of a β-cyclodextrin inclusion-complex nano-delivery platform to solubilize and follicularly target a multi-active botanical AGA regimen — combining a previously unavailable nano-formulation chemistry with a concomitant oral/topical clinical protocol.
What FollowedSince publication, cyclodextrin-based and 'nano-encapsulated' delivery claims have proliferated across the hair-loss and topical-cosmeceutical categories. The combined oral + topical, nano-enabled architecture introduced here is now widely emulated, though the underlying inclusion-complex IP remains proprietary to our program.
- 2025
An Uncontrolled Innovative Test of Cryo-Chilled Carbon Dioxide as a Novel Amplification of a Nano-Botanical Multi-Acting Therapy in Advanced-Stage Androgenetic Alopecia
Niedbala S, Campbell E, Young L, Marcovici G. Journal of Complementary Research and Alternative Medicine 2(1):1–9 (CryoConcepts LP × TrichoCyte, LLC)
Innovative-practice report in six advanced-stage AGA volunteers (5 male, 1 female) using a once-weekly cryo-chilled, CO₂-bolstered hydrogel iteration of the previously published nano-botanical formula, with daily oral and topical concomitants. A profoundly accelerated phenotypic reversal was observed by day 90 — sufficient to terminate the planned 270-day protocol 180 days ahead of schedule.
Significance — First-in-FieldFirst-in-field combination of cryo-analgesia and transdermal CO₂ enhancement with a nano-enabled botanical AGA regimen — a wholly novel point-of-service delivery modality that compresses prior 9-month response timelines into 90 days, including in advanced-stage phenotypes historically considered refractory.
What FollowedCryo and carboxy modalities had been described independently in dermatology for decades; this paper is the first to integrate them as a delivery amplifier for an oral/topical botanical AGA platform. We anticipate the same pattern of category-wide adoption that followed each of our earlier landmark publications. Formal intellectual-property protection around this combined device-plus-formulation approach has been explored in discussion with our cryo-delivery collaborators but has not, to date, been filed — individually or jointly.
A Pattern of Priority
Read together, these six papers describe a single arc: from the first randomized clinical proof of botanical 5α-reductase inhibition (2002), to the transcriptomic re-framing of AGA as an inflammatory disease (2011), to head-to-head outperformance of finasteride at the bench (2016), to nano-enabled inclusion-complex delivery (2020), and most recently to cryo-carboxy amplification of that same platform (2025). In every instance, the broader category moved — formulations, mechanism-of-action language, and clinical positioning — in the direction we had already established in the peer-reviewed record. The underlying chemistry and nano-delivery systems remain proprietary to our program; the cryo-carboxy amplification approach is the subject of ongoing collaborative exploration rather than filed IP.